133 related articles for article (PubMed ID: 12829671)
1. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T;
J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study.
Abete-Fornara G; Bintintan Socaciu P; Fanizzi C; Fiore G; Locatelli M; Caroli M
J Neurooncol; 2023 Dec; 165(3):561-568. PubMed ID: 38108984
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.
Kato Y; Holm DA; Okollie B; Artemov D
Neuro Oncol; 2010 Jan; 12(1):71-9. PubMed ID: 20150369
[TBL] [Abstract][Full Text] [Related]
5. Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas.
Pérez-García VM; Ayala-Hernández LE; Belmonte-Beitia J; Schucht P; Murek M; Raabe A; Sepúlveda J
PLoS Comput Biol; 2019 Jul; 15(7):e1006778. PubMed ID: 31306418
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
9. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
10. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Pace A; Vidiri A; Galiè E; Carosi M; Telera S; Cianciulli AM; Canalini P; Giannarelli D; Jandolo B; Carapella CM
Ann Oncol; 2003 Dec; 14(12):1722-6. PubMed ID: 14630675
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
[TBL] [Abstract][Full Text] [Related]
13. Global and Gender Equity in Oligodendroglioma Research: A Comprehensive Bibliometric Analysis Following the COVID-19 Pandemic.
Malhotra K; Dagli MM; Gujral J; Santangelo G; Goyal K; Wathen C; Ozturk AK; Welch WC
Cureus; 2023 Dec; 15(12):e51161. PubMed ID: 38283488
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas.
Kurimoto M; Rockenbach Y; Kato A; Natsume A
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372381
[TBL] [Abstract][Full Text] [Related]
15. Formononetin: A Pathway to Protect Neurons.
Ma X; Wang J
Front Integr Neurosci; 2022; 16():908378. PubMed ID: 35910340
[TBL] [Abstract][Full Text] [Related]
16. Promising Chemotherapy for Malignant Pediatric Brain Tumor in Recent Biological Insights.
Zhou Q; Xu Y; Zhou Y; Wang J
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566032
[TBL] [Abstract][Full Text] [Related]
17. Oligodendroglioma: A Review of Management and Pathways.
Bou Zerdan M; Assi HI
Front Mol Neurosci; 2021; 14():722396. PubMed ID: 34675774
[TBL] [Abstract][Full Text] [Related]
18. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A
Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
20. Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.
Ruff MW; Buckner JC; Johnson DR; van den Bent MJ; Geurts M
Neurooncol Pract; 2019 Jan; 6(1):17-21. PubMed ID: 31386006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
